KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Common Equity (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Common Equity data on record, last reported at $45.5 billion in Q1 2025.

  • For Q1 2025, Common Equity fell 7.39% year-over-year to $45.5 billion; the TTM value through Mar 2025 reached $45.5 billion, down 7.39%, while the annual FY2025 figure was $45.5 billion, 9.74% down from the prior year.
  • Common Equity reached $45.5 billion in Q1 2025 per TAK's latest filing, down from $49.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $49.1 billion in Q1 2024 and bottomed at $45.5 billion in Q1 2025.
  • Average Common Equity over 5 years is $48.1 billion, with a median of $48.9 billion recorded in 2022.
  • Peak YoY movement for Common Equity: grew 12.65% in 2021, then fell 7.39% in 2025.
  • A 5-year view of Common Equity shows it stood at $48.9 billion in 2021, then decreased by 0.02% to $48.9 billion in 2022, then decreased by 1.77% to $48.0 billion in 2023, then increased by 2.18% to $49.1 billion in 2024, then fell by 7.39% to $45.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $45.5 billion in Q1 2025, $49.1 billion in Q1 2024, and $48.0 billion in Q1 2023.